Business Wire

Independent Test Results confirm an inhibitory effect on the novel coronavirus (SARS-CoV-2) by Panasonic’s air conditioner with nanoe™ X

Share

Panasonic Corporation today announced that, in a European first, Texcell*1, a global contract research organisation, has certified the inhibitory effect on the novel coronavirus (SARS-CoV-2) by an air conditioner with nanoe™ X. Texcell verified 91.4% of the inhibitory effect on the novel coronavirus in a space of 6.7m3 over 8 hours.

nanoe™ X is a technology that collects invisible moisture in the air and applies a high voltage to it to produce “hydroxyl radicals contained in water”. Hydroxyl radicals inhibit the growth of pollutants such as certain bacteria and viruses. They are characterised by being strongly oxidative and highly reactive, hence a short life span. Contained in tiny water particles, nanoe™ X has a long lifespan and can spread over long distances. It has an inhibitory effect on both airborne and adhered substances.

In September 2020, and in collaboration with Texcell*1, Panasonic verified the inhibitory effect of the nanoe™ X technology with the benefits of hydroxyl radicals on the novel coronavirus in a small test space of 45L using nanoe™ X generator. For further investigation, Panasonic challenged to test using an air conditioner with nanoe™ X in a larger test space. Even in these difficult circumstances, Texcell has now certified that the nanoe™ X does have a 91.4% inhibitory effect on the novel coronavirus in the actual space of 6.7m3 over 8 hours using the air conditioner with nanoe™ X. This testing was carried out in a closed laboratory environment and was not designed to assess its efficacy in uncontrolled living spaces.

Panasonic has been conducting research on nanoe™ Technology over the past 20 years since 1997 and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*2.

Panasonic will continue to pursue the potential of nanoe™ X technology to address possible risks associated with air pollution such as new pathogenic microorganisms, to create healthy environments for people around the world.

For reference:
Testing the inhibitory effect of air conditioner with nanoe™ X on the novel coronavirus (SARS-CoV-2) in a space of 6.7m3 . 

Overview
A comparative verification was conducted in a space of 6.7m3 containing the novel coronavirus. (SARS-CoV-2)

Results
Over 91% of novel coronavirus (SARS-CoV-2) activity was inhibited within 8 hours.

Note: This verification was designed to generate basic research data on the effects of nanoe™ X on the novel coronavirus in laboratory conditions different from those found in living spaces.

Methodology and data
Organisation :Texcell (France)
Subject :Novel coronavirus (SARS-CoV-2)
Device :Air conditioner with nanoe™ X (Etherea model CS-Z25VKEW)
Method:

  • The Etherea air conditioner with nanoe™ X is installed in a space of 6.7m3.
  • Gauze saturated with SARS-CoV-2 virus solution was exposed to an air conditioner with nanoe™ X from a distance of 0.7m in a 6.7m3 room for 24 hours.
  • The virus infectious titre was measured and used to calculate the inhibition rate.

Test result

Test subject

Inhibition rate

Capacity

Hours

SARS-CoV-2

42.4%

6.7 m3

4 hours

SARS-CoV-2

91.4%

6.7 m3

8 hours

SARS-CoV-2

99.7%

6.7m3

24 hours

 

Notes:
*1: Texcell is a global contract research organisation that specialises in viral testings, viral clearance, immunoprofiling and R&D or GMP cell banking, for your R&D, GClP, GLP and GMP projects.

With more than 30 years of experience and roots within the Pasteur Institute in Paris, Texcell has a long recognized expertise in viral testing with a broad range of protocols for the detection of adventitious agents.

Texcell is the first spin-off of the Pasteur institute of Paris created in 1997.

*2: Main releases on verification cases
- May 12, 2009:Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012:Suppression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014:Nano-sized electrostatic atomised water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Contact information

Media Contact
Tanya Houston, Wildwood PR
tanya.houston@wildwoodpr.com
Tel: +44 (0)7711 617491

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 11:00:00 EETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 09:30:00 EETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 23:58:00 EETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 21:15:00 EETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

Tigo Energy Raises $20 Million in Funding14.1.2021 19:33:00 EETPress release

Tigo Energy, Inc., the worldwide leader in Flex-MLPE (Module Level Power Electronics) today announced a $20 million round of investment, led by Energy Growth Momentum. “2020 has been a breakout year for Tigo and 2021 has the potential for even greater success,” stated Zvi Alon, Chairman and CEO of Tigo. “We are excited to have the EG Momentum team’s support and their working capital will enable us to better serve our current customer base and invest in the future expansion with new customers, new partners and new projects.” The investment will be used to improve upon existing products and develop next generation solutions that maximize returns for PV customers. A portion of the new funds will be used to efficiently and effectively scale. Tigo’s growth has accelerated significantly recently as the company’s products have reached more customer segments and countries throughout the world. With over 40,000 installations in over 100 countries on all 7 continents, Tigo systems generate more

Samsung’s Newest 108Mp Mobile Image Sensor with Advanced Features Captures More Details and Produces Sharper Results14.1.2021 19:00:00 EETPress release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 108-megapixel (Mp) mobile image sensor, Samsung ISOCELL HM3. With a wide spectrum of advanced sensor technologies, the HM3 can capture sharper and more vivid images in ultra-high resolution with faster auto-focus and extended dynamic range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005430/en/ ISOCELL HM3 - 108 megapixel image sensor (Graphic: Business Wire) “While a pixel is just a single dot of color, when in millions, these dots can be transformed into stunning snapshots of life. With more pixels, images are sharper, with fuller details that can maintain their integrity even when enlarged. Samsung has been at the forefront of bringing the most pixels to mobile image sensors as well as various supporting technologies that take sensor performances to the next level,” said Duckhyun Chang, executive vice p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom